CL2024002106A1 - Proteina de fusión de unión a vegf y tie2 - Google Patents
Proteina de fusión de unión a vegf y tie2Info
- Publication number
- CL2024002106A1 CL2024002106A1 CL2024002106A CL2024002106A CL2024002106A1 CL 2024002106 A1 CL2024002106 A1 CL 2024002106A1 CL 2024002106 A CL2024002106 A CL 2024002106A CL 2024002106 A CL2024002106 A CL 2024002106A CL 2024002106 A1 CL2024002106 A1 CL 2024002106A1
- Authority
- CL
- Chile
- Prior art keywords
- fusion protein
- vegf
- binding fusion
- methods
- tie2 binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299177P | 2022-01-13 | 2022-01-13 | |
| US202263310359P | 2022-02-15 | 2022-02-15 | |
| US202263335805P | 2022-04-28 | 2022-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002106A1 true CL2024002106A1 (es) | 2025-03-28 |
Family
ID=87279731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002106A CL2024002106A1 (es) | 2022-01-13 | 2024-07-11 | Proteina de fusión de unión a vegf y tie2 |
| CL2025002473A CL2025002473A1 (es) | 2022-01-13 | 2025-08-18 | Vegf y proteína de fusión de unión a tie2 y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002473A CL2025002473A1 (es) | 2022-01-13 | 2025-08-18 | Vegf y proteína de fusión de unión a tie2 y sus usos. |
Country Status (16)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250128899A (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 맵틱스 | Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도 |
| WO2026036282A1 (en) * | 2024-08-13 | 2026-02-19 | Pentavision Biosciences Limited | Multispecific fusion proteins targeting angiogenic factors |
| US20260226178A1 (en) * | 2024-12-23 | 2026-08-06 | Ingenia Therapeutics, Inc. | Fusion Proteins Comprising a Tie2 Binding Domain |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3415533A1 (en) * | 2011-08-19 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Anti-tie2 antibodies uses thereof |
| JP2020501508A (ja) * | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| JP2021507723A (ja) * | 2017-12-05 | 2021-02-25 | ユニバーシティ オブ ワシントンUniversity of Washington | 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法 |
| WO2019235856A1 (ko) * | 2018-06-07 | 2019-12-12 | 기초과학연구원 | Tie2에 결합하는 항체 및 이의 용도 |
| EP3805265A4 (en) * | 2018-06-07 | 2022-07-06 | Institute for Basic Science | ANTIBODIES BINDING TO TIE2 AND USES THEREOF |
| JP2021529557A (ja) * | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. | 抗腫瘍免疫チェックポイント調節因子アンタゴニスト |
| JP7249060B2 (ja) * | 2018-08-17 | 2023-03-30 | トリカン・バイオテクノロジー・カンパニー・リミテッド | 抗血管新生融合タンパク質およびその使用 |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| AU2020385991A1 (en) * | 2019-11-21 | 2022-06-23 | Unity Biotechnology | Antibodies directed to Tie-2 and methods of use |
| CA3169967A1 (en) * | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
-
2023
- 2023-01-12 AU AU2023206363A patent/AU2023206363A1/en active Pending
- 2023-01-12 JP JP2024542028A patent/JP7884072B2/ja active Active
- 2023-01-12 EP EP23740846.3A patent/EP4463482A4/en active Pending
- 2023-01-12 WO PCT/US2023/060582 patent/WO2023137395A1/en not_active Ceased
- 2023-01-12 MX MX2024008737A patent/MX2024008737A/es unknown
- 2023-01-12 PE PE2024001601A patent/PE20260003A1/es unknown
- 2023-01-12 US US18/153,965 patent/US20230287109A1/en active Pending
- 2023-01-12 CR CR20240342A patent/CR20240342A/es unknown
- 2023-01-12 GE GEAP202416581A patent/GEAP202416581A/en unknown
- 2023-01-12 CA CA3242904A patent/CA3242904A1/en active Pending
- 2023-01-12 KR KR1020247027000A patent/KR20250005053A/ko active Pending
- 2023-01-12 IL IL314219A patent/IL314219A/en unknown
-
2024
- 2024-07-11 CL CL2024002106A patent/CL2024002106A1/es unknown
- 2024-07-12 DO DO2024000136A patent/DOP2024000136A/es unknown
- 2024-07-14 JO JOJO/P/2024/0158A patent/JOP20240158A1/ar unknown
- 2024-08-12 CO CONC2024/0010934A patent/CO2024010934A2/es unknown
-
2025
- 2025-08-18 CL CL2025002473A patent/CL2025002473A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314219A (en) | 2024-09-01 |
| KR20250005053A (ko) | 2025-01-09 |
| GEAP202416581A (en) | 2024-12-10 |
| JP7884072B2 (ja) | 2026-07-02 |
| WO2023137395A1 (en) | 2023-07-20 |
| DOP2024000136A (es) | 2024-10-15 |
| AU2023206363A1 (en) | 2024-08-15 |
| CL2025002473A1 (es) | 2025-11-14 |
| MX2024008737A (es) | 2024-09-11 |
| US20230287109A1 (en) | 2023-09-14 |
| JOP20240158A1 (ar) | 2024-07-14 |
| CA3242904A1 (en) | 2025-03-14 |
| JP2025503704A (ja) | 2025-02-04 |
| EP4463482A1 (en) | 2024-11-20 |
| EP4463482A4 (en) | 2026-05-06 |
| CR20240342A (es) | 2024-09-18 |
| PE20260003A1 (es) | 2026-01-06 |
| CO2024010934A2 (es) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002473A1 (es) | Vegf y proteína de fusión de unión a tie2 y sus usos. | |
| ECSP20014523A (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco | |
| CO6270370A2 (es) | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 | |
| CL2021000873A1 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. | |
| BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
| MX2021004045A (es) | Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco. | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| PE20091029A1 (es) | Anticuerpos anti-alfa 5 beta 1 | |
| AR068997A1 (es) | Anticuerpos contra el vegf completamente humano y sus metodos de uso | |
| UY37457A (es) | Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y | |
| PE20090245A1 (es) | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| MX2021012997A (es) | Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos. | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| WO2019030762A3 (en) | CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| MX2021006548A (es) | Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica. | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| AR121441A1 (es) | Anticuerpos anti-axl y composiciones |